Case closed: Neutrons settle 40-year debate on enzyme for drug design
Filter News
Area of Research
News Topics
- (-) Isotopes (13)
- 3-D Printing/Advanced Manufacturing (89)
- Advanced Reactors (9)
- Artificial Intelligence (13)
- Big Data (7)
- Bioenergy (30)
- Biology (12)
- Biomedical (10)
- Biotechnology (4)
- Buildings (38)
- Chemical Sciences (33)
- Clean Water (10)
- Climate Change (23)
- Composites (19)
- Computer Science (36)
- Coronavirus (14)
- Critical Materials (19)
- Cybersecurity (10)
- Decarbonization (34)
- Energy Storage (86)
- Environment (64)
- Exascale Computing (3)
- Fossil Energy (2)
- Frontier (3)
- Fusion (7)
- Grid (41)
- High-Performance Computing (9)
- Hydropower (2)
- Irradiation (1)
- ITER (1)
- Machine Learning (10)
- Materials (94)
- Materials Science (90)
- Mathematics (3)
- Mercury (3)
- Microelectronics (1)
- Microscopy (29)
- Molten Salt (3)
- Nanotechnology (41)
- National Security (6)
- Net Zero (3)
- Neutron Science (42)
- Nuclear Energy (22)
- Partnerships (16)
- Physics (29)
- Polymers (21)
- Quantum Computing (3)
- Quantum Science (12)
- Renewable Energy (1)
- Security (7)
- Simulation (4)
- Space Exploration (5)
- Statistics (1)
- Summit (6)
- Sustainable Energy (71)
- Transformational Challenge Reactor (5)
- Transportation (70)
Media Contacts
A tiny vial of gray powder produced at the Department of Energy’s Oak Ridge National Laboratory is the backbone of a new experiment to study the intense magnetic fields created in nuclear collisions.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.
“Made in the USA.” That can now be said of the radioactive isotope molybdenum-99 (Mo-99), last made in the United States in the late 1980s. Its short-lived decay product, technetium-99m (Tc-99m), is the most widely used radioisotope in medical diagnostic imaging. Tc-99m is best known ...